Guidance for Industry - Assay Development
Assay Development for Immunogenicity Testing of Therapeutic Proteins, Draft Guidance http://www.ipm-biotech.de/fileadmin/user_upload/pdf/guidelines/FDA-GUIDANCE-Assay-Development-Immunogenicity-Testing.pdf
Assay Development for Immunogenicity Testing of Therapeutic Proteins, Draft Guidance
http://www.ipm-biotech.de/fileadmin/user_upload/pdf/guidelines/FDA-GUIDANCE-Assay-Development-Immunogenicity-Testing.pdf
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>Guidance</strong> <strong>for</strong> <strong>Industry</strong><br />
<strong>Assay</strong> <strong>Development</strong> <strong>for</strong><br />
Immunogenicity Testing of<br />
Therapeutic Proteins<br />
Additional copies are available from:<br />
Office of Communication<br />
Division of Drug In<strong>for</strong>mation, WO51, Room 2201<br />
Center <strong>for</strong> Drug Evaluation and Research<br />
Food and Drug Administration<br />
10903 New Hampshire Ave.<br />
Silver Spring, MD 20993<br />
(Tel) 301-796-3400; (Fax) 301-847-8714<br />
druginfo@fda.hhs.gov<br />
http://www.fda.gov/AnimalVeterinary/<strong>Guidance</strong>ComplianceEn<strong>for</strong>cement/<strong>Guidance</strong><strong>for</strong><strong>Industry</strong>/default.htm<br />
Office of Communication, Outreach, and<br />
<strong>Development</strong>, HFM-40<br />
Center <strong>for</strong> Biologics Evaluation and Research<br />
Food and Drug Administration<br />
1401 Rockville Pike, Suite 200N, Rockville, MD 20852-1448<br />
ocod@fda.hhs.gov<br />
http://www.fda.gov/BiologicsBloodVaccines/<strong>Guidance</strong>ComplianceRegulatoryIn<strong>for</strong>mation/<strong>Guidance</strong>s/default.htm<br />
(Tel) 800-835-4709 or 301-827-1800<br />
U.S. Department of Health and Human Services<br />
Food and Drug Administration<br />
Center <strong>for</strong> Drug Evaluation and Research (CDER)<br />
Center <strong>for</strong> Biologics Evaluation and Research (CBER)<br />
December 2009<br />
CMC